Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 16.
doi: 10.1097/AOG.0000000000006091. Online ahead of print.

Extended-Release Buprenorphine for Treatment of Opioid Use Disorder During Pregnancy and Postpartum

Nia Bhadra-Heintz  1 , Rebecca Schapiro, Navid Roder, Emily Casey, Julia Carney, Judy Chertok, Margaret Lowenstein
Affiliations

Extended-Release Buprenorphine for Treatment of Opioid Use Disorder During Pregnancy and Postpartum

Nia Bhadra-Heintz et al. Obstet Gynecol. .

Abstract

Buprenorphine use in pregnancy and postpartum for individuals with opioid use disorder (OUD) decreases maternal and fetal morbidity and mortality. Extended-release buprenorphine overcomes barriers to sublingual buprenorphine, but very limited data are available regarding use in the perinatal period. We aimed to describe extended-release buprenorphine uptake and associated recovery and pregnancy outcomes in a case series of 15 pregnant and postpartum individuals with OUD. Reasons for extended-release buprenorphine initiation included nausea, burdensome multiple daily dosing of sublingual buprenorphine, and persistent cravings. Postinitiation, all patients demonstrated increased buprenorphine adherence, total cessation of nonprescribed opioids, and a reduction in other substance use. There were no identified maternal or neonatal side effects. Our data provide early evidence for safety, adherence, and reduced substance use among perinatal patients with OUD treated with extended-release buprenorphine.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure The authors did not report any potential conflicts of interest.

References

    1. Margerison CE, Roberts MH, Gemmill A, Goldman-Mellor S. Pregnancy-associated deaths due to drugs, suicide, and homicide in the United States, 2010–2019. Obstet Gynecol 2022;139:172–80. doi: 10.1097/AOG.0000000000004649 - DOI
    1. Schiff DM, Nielsen T, Terplan M, Hood M, Bernson D, Diop H, et al. Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol 2018;132:466–74. doi: 10.1097/AOG.0000000000002734 - DOI
    1. Chokshi R, Parish S, Aponte N, Ural S, O'Brien J. Current research on opioid use disorder (OUD) in pregnancy with emphasis on medication-assisted treatment (MAT). Med Res Arch 2024;12. doi: 10.18103/mra.v12i8.5736 - DOI
    1. Henkhaus LE, Buntin MB, Henderson SC, Lai P, Patrick SW. Disparities in receipt of medications for opioid use disorder among pregnant women. Subst Abus 2022;43:508–13. doi: 10.1080/08897077.2021.1949664 - DOI
    1. Krans EE, Kim JY, Chen Q, Rothenberger SD, James AE III, Kelley D, et al. Outcomes associated with the use of medications for opioid use disorder during pregnancy. Addiction 2021;116:3504–14. doi: 10.1111/add.15582 - DOI

LinkOut - more resources